Clinical

Dataset Information

0

Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies


ABSTRACT: This single center, Phase 1b, prospective, dose limiting toxicity (DLT)-clearing study, will assess the safety and efficacy of intravenously administered PROMITIL in combination with FOLFOX in cancer patients with inoperable, locally advanced or metastatic GI solid tumors. Based on previous clinical results, we hypothesized that the addition of PROMITIL to FOLFOX, a treatment protocol consisting of oxaliplatin and fluoropyrimidine and commonly used to treat gastrointestinal (GI) malignancies, may enhance the overall efficacy of this combination regimen while maintain a reasonable safety profile.

DISEASE(S): Gastro-intestinal Intraepithelial Neoplasia,Solid Tumors,Neoplasms,Cancer

PROVIDER: 2365421 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2015-07-31 | E-GEOD-59996 | biostudies-arrayexpress
2015-07-31 | GSE59996 | GEO
2013-09-01 | E-GEOD-47169 | biostudies-arrayexpress
| PRJEB7981 | ENA
2013-09-01 | GSE47169 | GEO
| PRJNA924021 | ENA
2019-08-30 | GSE119058 | GEO
2023-11-21 | GSE214792 | GEO
2023-11-21 | GSE214793 | GEO
2023-11-21 | GSE214791 | GEO